Annals of Surgical Oncology

, Volume 25, Issue 3, pp 617–625 | Cite as

Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia

  • Rebecca L. Read
  • Christine M. Madronio
  • Anne E. Cust
  • Chris Goumas
  • Caroline G. Watts
  • Scott Menzies
  • Austin M. Curtin
  • Graham Mann
  • John F. Thompson
  • Rachael L. Morton



Follow-up practices after diagnosis and treatment of primary cutaneous melanoma vary considerably. We aimed to determine factors associated with recommendations for follow-up setting, frequency, skin surveillance, and concordance with clinical guidelines.


The population-based Melanoma Patterns of Care study documented clinicians’ recommendations for follow-up for 2148 patients diagnosed with primary cutaneous melanoma over a 12-month period (2006/2007) in New South Wales, Australia. Multivariate log binomial regression models adjusted for patient and lesion characteristics were used to examine factors associated with follow-up practices.


Of 2158 melanomas, Breslow thickness was < 1 mm for 57% and ≥ 1 mm for 30%, while in situ melanomas accounted for 13%. Follow-up was recommended for 2063 patients (96%). On multivariate analysis, factors associated with a recommendation for follow-up at a specialist center were Breslow thickness ≥ 1 mm [prevalence ratio (PR) 1.05, 95% confidence interval (CI) 1.01–1.09] and initial treatment at a specialist center (PR 1.12, 95% CI 1.08–1.16). Longer follow-up intervals of > 3 months were more likely to be recommended for females, less likely for people living in rural compared with urban areas, and less likely for thicker (≥ 1 mm) melanomas compared with in situ melanomas. Skin self-examination was encouraged in 84% of consultations and was less likely to be recommended for patients ≥ 70 years (PR 0.88, 95% CI 0.84–0.93) and for those with thicker (≥ 1 mm) melanomas (PR 0.92, 95% CI 0.86–0.99). Only 1% of patients were referred for psychological care.


Follow-up recommendations were generally consistent with Australian national guidelines for management of melanoma, however some variations could be targeted to improve patient outcomes.



We are indebted to Prof. Bruce K Armstrong, DPhil, FRACP, FAFPHM, FAA for his guidance with the analysis of data from the Melanoma Patterns of Care study. This study was funded by the Cancer Institute NSW, with additional financial support provided by Melanoma Institute Australia and the NSW Melanoma Network. Anne E. Cust was supported by an NHMRC Career Development Fellowship (no. 1063593) and a Cancer Institute NSW Fellowship (no. 15/CDF/1- 14). John F. Thompson was supported by the Melanoma Foundation of the University of Sydney. Rachael L. Morton was supported by an Australian National Health and Medical Research (NHMRC) Fellowship (no. 1054216)..



Supplementary material

10434_2017_6319_MOESM1_ESM.docx (43 kb)
Supplementary material 1 (DOCX 42 kb)


  1. 1.
    Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) books: Melanoma of the skin. Canberra: AIHW.–books [Accessed February 2017] 2017.
  2. 2.
    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer (AJCC) Eighth Edition Cancer Staging Manual. CA: A Cancer Journal 2017; In press.Google Scholar
  3. 3.
    Turner RM, Bell KJ, Morton RL, et al. Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol. 2011;29:4641–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010;146:265–72.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Titus-Ernstoff L, Perry AE, Spencer SK, et al. Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol. 2006;142:433-8.CrossRefPubMedGoogle Scholar
  6. 6.
    Youlden DR, Youl PH, Soyer HP, Aitken JF, Baade PD. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982–2010. JAMA Dermatol. 2014;150:526–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Francken AB, Bastiaannet E, Hoekstra HJ. Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol. 2005;6:608–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol. 1999;140:249–54.CrossRefPubMedGoogle Scholar
  9. 9.
    Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014;32:2479–85.CrossRefPubMedGoogle Scholar
  10. 10.
    Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14:1924–33.CrossRefPubMedGoogle Scholar
  11. 11.
    McPherson M, Elwood M, English DR, Baade PD, Youl PH, Aitken JF. Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol .2006;54:783-92.CrossRefPubMedGoogle Scholar
  12. 12.
    Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(7):86–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Cromwell KD, Ross MI, Xing Y, et al. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012;22:376–85.CrossRefPubMedGoogle Scholar
  14. 14.
    World Health Organisation. international classification of diseases for oncology (ICD-O-3). Geneva: World Health Organisation; 2000.Google Scholar
  15. 15.
    Pink B. SEIFA Technical Report 2011. Australian Bureau of Statistics 2013;2033.0.55.001.Google Scholar
  16. 16.
    McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157:940-3.CrossRefPubMedGoogle Scholar
  17. 17.
    Petersen MR, Deddens JA. A comparison of two methods for estimating prevalence ratios. BMC Med Res Methodol. 2008;8:9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.CrossRefGoogle Scholar
  19. 19.
    Australian Cancer Network. Clinical Practice Guidelines. The management of cutaneous melanoma. National Health and Medical Research Council (NHMRC) 1999:1–81.Google Scholar
  20. 20.
    Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol. 2009;27:5445–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Geller AC, Zhang Z, Sober AJ, et al. The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985–1999. J Am Acad Dermatol. 2003;48:34–41.CrossRefPubMedGoogle Scholar
  22. 22.
    Hanrahan PF, Hersey P, D’Este CA. Factors involved in presentation of older people with thick melanoma. Med J Aust. 1998;169:410-4.PubMedGoogle Scholar
  23. 23.
    McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet. 1988;166:497–502.PubMedGoogle Scholar
  24. 24.
    Scally CP, Wong SL. Intensity of follow-up after melanoma surgery. Ann Surg Oncol. 2014;21:752–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Moloney FJ, Guitera P, Coates E, et al. Detection of primary melanoma in individuals at extreme high risk: a prospective 5-year follow-up study. JAMA Dermatol. 2014;150:819–27.CrossRefPubMedGoogle Scholar
  26. 26.
    Watts CG, Dieng M, Morton RL, Mann GJ, Menzies SW, Cust AE. Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. Br J Dermatol .2015;172:33–47.CrossRefPubMedGoogle Scholar
  27. 27.
    Damude S, Hoekstra-Weebers JE, Francken AB, Ter Meulen S, Bastiaannet E, Hoekstra HJ. The MELFO-study: prospective, randomized, clinical trial for the evaluation of a stage-adjusted reduced follow-up schedule in cutaneous melanoma patients-results after 1 year. Ann Surg Oncol. 2016;23:2762–71.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Australian Cancer Network. Clinical practice guidelines for the management of melanoma in Australia and New Zealand: evidence-based best practice guidelines. National Health and Medical Research Council (Australia), Commonwealth of Australia 2008; Canberra, ACT.:1-225.Google Scholar
  29. 29.
    Coit DG, Thompson JA, Andtbacka R, et al. Melanoma, Version 4.2014. J Natl Comprehensive Cancer Netw. 2014;12:621–9CrossRefGoogle Scholar
  30. 30.
    National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Melanoma United States. 2009;Version 2.0 2009.Google Scholar
  31. 31.
    Rychetnik L, Morton RL, McCaffery K, Thompson JF, Menzies SW, Irwig L. Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians’ perspectives and models of care. BMC Health Serv Res. 2012;12:468.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Mitchell J, Callaghan P, Street J, Neuhaus S, Bessen T. The experience of melanoma follow-up care: an online survey of patients in australia. J Skin Cancer. 2014;2014:429149.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Morton RL, Rychetnik L, McCaffery K, Thompson JF, Irwig L. Patients’ perspectives of long-term follow-up for localised cutaneous melanoma. Eur J Surg Oncol. 2013;39:297–303.CrossRefPubMedGoogle Scholar
  34. 34.
    Rychetnik L, McCaffery K, Morton RL, Thompson JF, Menzies SW, Irwig L. Follow-up of early stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. J Surg Oncol. 2013;107:463–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Varey AHR, Madronio CM, Cust AE, et al. Poor adherence to national clinical management guidelines: a population-based, cross-sectional study of the surgical management of melanoma in New South Wales, Australia. Ann Surg Oncol. 2017;24:2080–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Dieng M, Butow PN, Costa DSJ, et al. Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial. J Clin Oncol. 2016;34:4405–14.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Rebecca L. Read
    • 1
    • 2
  • Christine M. Madronio
    • 3
  • Anne E. Cust
    • 1
    • 3
  • Chris Goumas
    • 1
  • Caroline G. Watts
    • 3
  • Scott Menzies
    • 4
  • Austin M. Curtin
    • 4
  • Graham Mann
    • 4
  • John F. Thompson
    • 1
    • 5
  • Rachael L. Morton
    • 1
    • 6
  1. 1.Melanoma Institute Australia, The University of SydneyNorth SydneyAustralia
  2. 2.Calvary Health CareBruceAustralia
  3. 3.Cancer Epidemiology and Prevention Research, Sydney School of Public HealthThe University of SydneyCamperdownAustralia
  4. 4.Sydney Medical SchoolThe University of Sydney and the Sydney Melanoma Diagnostic Centre, Royal Prince Alfred HospitalCamperdownAustralia
  5. 5.Department of SurgeryThe University of SydneyCamperdownAustralia
  6. 6.NHMRC Clinical Trials CentreThe University of SydneyCamperdownAustralia

Personalised recommendations